Tokyo, Japan – September 3, 2019 – MicroPort® CRM Japan Co. Ltd. is pleased to announce it has started direct sales operations today, with the first four implants of the KORA™ pacemakers that have been performed in several regions in Japan.
MicroPort® CRM Japan is a subsidiary of MicroPort® CRM, headquartered in greater Paris, France, and established in August 2018 with the objective to take over the direct distribution of CRM products in Japan from September 1, 2019.
MicroPort® CRM Japan will start introducing ENO™ in Japan, a new range of pacemakers with a volume of only 8cc. ENO™ pacemakers feature AutoMRI™ technology, allowing patients implanted with compatible leads to undergo MRI (Magnetic Resonance Imaging) scans in either 1.5 Tesla or 3 Tesla machines. AutoMRI™ automatically switches in and out of MRI mode upon detection of the MR field, ensuring appropriate pacemaker operation during the scan and allowing patients to benefit from optimal pacing settings right up to and just after the scan.
“I am very proud of what the Japanese MicroPort® CRM team has achieved in just a few months to be ready to operate in Japan”, said Noboru Shimizu, Vice President, Japan Country Manager. “Thanks to the skills of the team and the quality of our products, I am confident that we will be able to further strengthen the trust that physicians place in the MicroPort® CRM brand.”
About MicroPort® CRM
Pioneering physiological therapies in cardiac rhythm management. Driven by our expert R&D teams and state-of-the-art manufacturing facilities across the globe, MicroPort® CRM conceives, designs and develops solutions for the management of cardiac rhythm disorders and heart failure. Headquartered in greater Paris, our precise technologies are manufactured in France, Italy, the Dominican Republic; and for the Chinese market, in China. MicroPort® CRM is part of MicroPort® Scientific Corporation.
MicroPort Scientific Corporation (the “Group”) is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.
For more information, please refer to: www.microport.com
Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, anticipate”, “project”, “estimate”, “predict”, “is confident”, “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®‘s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.
This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.
All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989